These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 16709306)

  • 21. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R; Haftbaradaran A; Ravakhah K
    J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
    Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
    Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD; Wolter DJ
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.
    Franzetti F; Grassini A; Piazza M; Degl'innocenti M; Bandera A; Gazzola L; Marchetti G; Gori A
    Infection; 2006 Feb; 34(1):9-16. PubMed ID: 16501896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral levofloxacin in the treatment of community-acquired pneumonia.
    Nicodemo AC; Lima Nicodemo E; Idrahim KY
    Braz J Infect Dis; 2000 Apr; 4(2):61-6. PubMed ID: 10795070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
    Schaeffer AJ; Wu SC; Tennenberg AM; Kahn JB
    J Urol; 2005 Jul; 174(1):161-4. PubMed ID: 15947609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
    Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the treatment of Pseudomonas aeruginosa pneumonia.
    El Solh AA; Alhajhusain A
    J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventilator-associated pneumonia caused by Pseudomonas infection.
    Dunn M; Wunderink RG
    Clin Chest Med; 1995 Mar; 16(1):95-109. PubMed ID: 7768096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bacterial etiology of nosocomial pneumonia and antimicrobial resistance in patients with and without antimicrobial treatment].
    Weyland B; Perazzi B; García S; Rodríguez C; Vay C; Famiglietti A
    Rev Argent Microbiol; 2011; 43(1):18-23. PubMed ID: 21491061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
    Ray GT; Baxter R; DeLorenze GN
    Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
    Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
    An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.
    Cao B; Wang H; Sun H; Zhu Y; Chen M
    J Hosp Infect; 2004 Jun; 57(2):112-8. PubMed ID: 15183240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levofloxacin for the treatment of community-acquired pneumonia.
    Lynch JP; File TM; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):725-42. PubMed ID: 17140350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.